{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021205","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.286359+00:00","generated_at":"2026-06-15T04:24:19.782161+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Finch Therapeutics dismisses Deloitte, appoints Wolf & Company as new auditor effective May 12, 2023","bullets":["Audit Committee approved dismissal of Deloitte and engagement of Wolf & Company, effective May 12, 2023.","Decision driven by goal of reducing ongoing costs related to annual audit.","Deloitte's reports for 2021 and 2022 contained no adverse opinion except a going concern explanatory paragraph.","Material weakness in internal controls as of Dec 31, 2019 was remediated as of Dec 31, 2021.","No disagreements or reportable events with Deloitte during 2021, 2022, and through May 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021205","json":"https://secwatch.observer/filing/0000950170-23-021205.json","markdown":"https://secwatch.observer/filing/0000950170-23-021205.md","text":"https://secwatch.observer/filing/0000950170-23-021205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/0000950170-23-021205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/fnch-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:24:19.782161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c0ea98b1ff32617d42ca779bb64533da48375d4","claim":"Finch Therapeutics Group, Inc. engaged Wolf & Company, P.C. as its auditor.","evidence_excerpt":"Also on May 8, 2023, the Audit Committee approved the engagement, effective May 12, 2023, of Wolf & Company, P.C. (“Wolf”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/0000950170-23-021205-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Wolf & Company, P.C."}],"fact_type":"auditor_change"},{"claim_id":"edffbf387c3479c75b93ff7d2648e8c57f7f867e","claim":"Finch Therapeutics Group, Inc. dismissed Deloitte & Touche LLP as its auditor.","evidence_excerpt":"On May 8, 2023, the Audit Committee of the Board of Directors (the “Audit Committee”) of Finch Therapeutics Group, Inc. (the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective May 12, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023021205/0000950170-23-021205-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Deloitte & Touche LLP"},{"label":"Successor","value":"Wolf & Company, P.C."}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}